Stephanie Baum
At a time when self-insured employers are searching for ways to address escalating healthcare costs, the rise of GLP-1 drugs for weight loss poses some interesting questions for employers. Could investment in these pricey drugs as a health benefit stem the cost of chronic conditions in the long term? How do employers decide who should get access to these drugs, originally developed for Type 2 diabetes? How can employers be sure employees will develop healthy habits like changing diet and exercise routines so they get a return on their investment?
In a conversation with MedCity News Editor-in-Chief Arundhati Parmar, Personify Health Chief Medical Officer Jeff Jacques talks about the different types of GLP-1 drugs, what portion of employers currently offer the medications, and how many employers are considering making them part of their health benefit offering in the future.